Literature DB >> 25271084

MBD5 haploinsufficiency is associated with sleep disturbance and disrupts circadian pathways common to Smith-Magenis and fragile X syndromes.

Sureni V Mullegama1, Loren Pugliesi2, Brooke Burns2, Zalak Shah2, Raiha Tahir2, Yanghong Gu1, David L Nelson1, Sarah H Elsea3.   

Abstract

Individuals with autism spectrum disorders (ASD) who have an identifiable single-gene neurodevelopmental disorder (NDD), such as fragile X syndrome (FXS, FMR1), Smith-Magenis syndrome (SMS, RAI1), or 2q23.1 deletion syndrome (del 2q23.1, MBD5) share phenotypic features, including a high prevalence of sleep disturbance. We describe the circadian deficits in del 2q23.1 through caregiver surveys in which we identify several frequent sleep anomalies, including night/early awakenings, coughing/snoring loudly, and difficulty falling asleep. We couple these findings with studies on the molecular analysis of the circadian deficits associated with haploinsufficiency of MBD5 in which circadian gene mRNA levels of NR1D2, PER1, PER2, and PER3 were altered in del 2q23.1 lymphoblastoid cell lines (LCLs), signifying that haploinsufficiency of MBD5 can result in dysregulation of circadian rhythm gene expression. These findings were further supported by expression microarrays of MBD5 siRNA knockdown cells that showed significantly altered expression of additional circadian rhythm signaling pathway genes. Based on the common sleep phenotypes observed in del 2q23.1, SMS, and FXS patients, we explored the possibility that MBD5, RAI1, and FMR1 function in overlapping circadian rhythm pathways. Bioinformatic analysis identified conserved putative E boxes in MBD5 and RAI1, and expression levels of NR1D2 and CRY2 were significantly reduced in patient LCLs. Circadian and mTOR signaling pathways, both associated with sleep disturbance, were altered in both MBD5 and RAI1 knockdown microarray data, overlapping with findings associated with FMR1. These data support phenotypic and molecular overlaps across these syndromes that may be exploited to provide therapeutic intervention for multiple disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25271084      PMCID: PMC4795052          DOI: 10.1038/ejhg.2014.200

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  38 in total

1.  Refinement of the Smith-Magenis syndrome critical region to approximately 950kb and assessment of 17p11.2 deletions. Are all deletions created equally?

Authors:  Christopher N Vlangos; Dwight K C Yim; Sarah H Elsea
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

2.  Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.

Authors:  C A Hoeffer; E Sanchez; R J Hagerman; Y Mu; D V Nguyen; H Wong; A M Whelan; R S Zukin; E Klann; F Tassone
Journal:  Genes Brain Behav       Date:  2012-02-15       Impact factor: 3.449

3.  Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder.

Authors:  Michael E Talkowski; Sureni V Mullegama; Jill A Rosenfeld; Bregje W M van Bon; Yiping Shen; Elena A Repnikova; Julie Gastier-Foster; Devon Lamb Thrush; Sekar Kathiresan; Douglas M Ruderfer; Colby Chiang; Carrie Hanscom; Carl Ernst; Amelia M Lindgren; Cynthia C Morton; Yu An; Caroline Astbury; Louise A Brueton; Klaske D Lichtenbelt; Lesley C Ades; Marco Fichera; Corrado Romano; Jeffrey W Innis; Charles A Williams; Dennis Bartholomew; Margot I Van Allen; Aditi Parikh; Lilei Zhang; Bai-Lin Wu; Robert E Pyatt; Stuart Schwartz; Lisa G Shaffer; Bert B A de Vries; James F Gusella; Sarah H Elsea
Journal:  Am J Hum Genet       Date:  2011-10-07       Impact factor: 11.025

4.  Length of uninterrupted CGG repeats determines instability in the FMR1 gene.

Authors:  E E Eichler; J J Holden; B W Popovich; A L Reiss; K Snow; S N Thibodeau; C S Richards; P A Ward; D L Nelson
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

5.  Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities.

Authors:  J C Hodge; E Mitchell; V Pillalamarri; T L Toler; F Bartel; H M Kearney; Y S Zou; W H Tan; C Hanscom; S Kirmani; R R Hanson; S A Skinner; R C Rogers; D B Everman; E Boyd; C Tapp; S V Mullegama; D Keelean-Fuller; C M Powell; S H Elsea; C C Morton; J F Gusella; B DuPont; A Chaubey; A E Lin; M E Talkowski
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

6.  Haploinsufficiency of MBD5 associated with a syndrome involving microcephaly, intellectual disabilities, severe speech impairment, and seizures.

Authors:  Stephen R Williams; Sureni V Mullegama; Jill A Rosenfeld; Aditi I Dagli; Eli Hatchwell; William P Allen; Charles A Williams; Sarah H Elsea
Journal:  Eur J Hum Genet       Date:  2009-11-11       Impact factor: 4.246

7.  Extended spectrum of MBD5 mutations in neurodevelopmental disorders.

Authors:  Céline Bonnet; Asma Ali Khan; Emmanuel Bresso; Charlène Vigouroux; Mylène Béri; Sarah Lejczak; Bénédicte Deemer; Joris Andrieux; Christophe Philippe; Anne Moncla; Irina Giurgea; Marie-Dominique Devignes; Bruno Leheup; Philippe Jonveaux
Journal:  Eur J Hum Genet       Date:  2013-02-20       Impact factor: 4.246

8.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

9.  The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype.

Authors:  Bregje W M van Bon; David A Koolen; Louise Brueton; Dominic McMullan; Klaske D Lichtenbelt; Lesley C Adès; Gregory Peters; Kate Gibson; Susan Moloney; Francesca Novara; Tiziano Pramparo; Bernardo Dalla Bernardina; Leonardo Zoccante; Umberto Balottin; Fausta Piazza; Vanna Pecile; Paolo Gasparini; Veronica Guerci; Marleen Kets; Rolph Pfundt; Arjan P de Brouwer; Joris A Veltman; Nicole de Leeuw; Meredith Wilson; Jayne Antony; Santina Reitano; Daniela Luciano; Marco Fichera; Corrado Romano; Han G Brunner; Orsetta Zuffardi; Bert B A de Vries
Journal:  Eur J Hum Genet       Date:  2009-10-07       Impact factor: 4.246

10.  Smith-Magenis syndrome results in disruption of CLOCK gene transcription and reveals an integral role for RAI1 in the maintenance of circadian rhythmicity.

Authors:  Stephen R Williams; Deborah Zies; Sureni V Mullegama; Michael S Grotewiel; Sarah H Elsea
Journal:  Am J Hum Genet       Date:  2012-05-10       Impact factor: 11.025

View more
  15 in total

Review 1.  Epigenetic mechanisms in diurnal cycles of metabolism and neurodevelopment.

Authors:  Weston T Powell; Janine M LaSalle
Journal:  Hum Mol Genet       Date:  2015-06-23       Impact factor: 6.150

2.  De Novo KAT5 Variants Cause a Syndrome with Recognizable Facial Dysmorphisms, Cerebellar Atrophy, Sleep Disturbance, and Epilepsy.

Authors:  Jonathan Humbert; Smrithi Salian; Periklis Makrythanasis; Gabrielle Lemire; Justine Rousseau; Sophie Ehresmann; Thomas Garcia; Rami Alasiri; Armand Bottani; Sylviane Hanquinet; Erin Beaver; Jennifer Heeley; Ann C M Smith; Seth I Berger; Stylianos E Antonarakis; Xiang-Jiao Yang; Jacques Côté; Philippe M Campeau
Journal:  Am J Hum Genet       Date:  2020-08-20       Impact factor: 11.025

3.  RAI1 Overexpression Promotes Altered Circadian Gene Expression and Dyssomnia in Potocki-Lupski Syndrome.

Authors:  Sureni V Mullegama; Joseph T Alaimo; Michael D Fountain; Brooke Burns; Amanda Hebert Balog; Li Chen; Sarah H Elsea
Journal:  J Pediatr Genet       Date:  2017-03-07

Review 4.  Clinical and Molecular Aspects of MBD5-Associated Neurodevelopmental Disorder (MAND).

Authors:  Sureni V Mullegama; Sarah H Elsea
Journal:  Eur J Hum Genet       Date:  2016-05-25       Impact factor: 4.246

5.  Systematic identification of genetic systems associated with phenotypes in patients with rare genomic copy number variations.

Authors:  F M Jabato; Pedro Seoane; James R Perkins; Elena Rojano; Adrián García Moreno; M Chagoyen; Florencio Pazos; Juan A G Ranea
Journal:  Hum Genet       Date:  2020-08-10       Impact factor: 4.132

6.  FMRP has a cell-type-specific role in CA1 pyramidal neurons to regulate autism-related transcripts and circadian memory.

Authors:  Jennifer C Darnell; Robert B Darnell; Kirsty Sawicka; Caryn R Hale; Christopher Y Park; John J Fak; Jodi E Gresack; Sarah J Van Driesche; Jin Joo Kang
Journal:  Elife       Date:  2019-12-20       Impact factor: 8.140

7.  Composite Sleep Problems Observed Across Smith-Magenis Syndrome, MBD5-Associated Neurodevelopmental Disorder, Pitt-Hopkins Syndrome, and ASD.

Authors:  Anusha Gandhi; Dihong Zhou; Joseph Alaimo; Edwin Chon; Michael D Fountain; Sarah H Elsea
Journal:  J Autism Dev Disord       Date:  2021-06

8.  Phenotypic and molecular convergence of 2q23.1 deletion syndrome with other neurodevelopmental syndromes associated with autism spectrum disorder.

Authors:  Sureni V Mullegama; Joseph T Alaimo; Li Chen; Sarah H Elsea
Journal:  Int J Mol Sci       Date:  2015-04-07       Impact factor: 5.923

9.  The Mendelian disorders of the epigenetic machinery.

Authors:  Hans Tomas Bjornsson
Journal:  Genome Res       Date:  2015-10       Impact factor: 9.043

10.  Identification of a RAI1-associated disease network through integration of exome sequencing, transcriptomics, and 3D genomics.

Authors:  Maria Nicla Loviglio; Christine R Beck; Janson J White; Marion Leleu; Tamar Harel; Nicolas Guex; Anne Niknejad; Weimin Bi; Edward S Chen; Isaac Crespo; Jiong Yan; Wu-Lin Charng; Shen Gu; Ping Fang; Zeynep Coban-Akdemir; Chad A Shaw; Shalini N Jhangiani; Donna M Muzny; Richard A Gibbs; Jacques Rougemont; Ioannis Xenarios; James R Lupski; Alexandre Reymond
Journal:  Genome Med       Date:  2016-11-01       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.